Barrott L, Foreman E. Staff sensitisation to therapeutic monoclonal antibodies resulting from workplace exposure: A case report. J Oncol Pharm Pract. 2020; 26:1282-1284

Bauters T, Vandenbroucke J. Development of a flowchart for risk assessment and allocation of preparation of monoclonal antibodies. J Oncol Pharm Pract. 2019; 25:187-191

Clark C. How can we protect cancer nurses from exposure to hazardous drugs?. Br J Nurs. 2021a; 30:(4)S4-S8

Clark C. Helping to protect cancer nurses from exposure to hazardous drugs. Br J Nurs. 2021b; 30:(18)S16-S20

Clark C. The need to protect cancer nurses from exposure to hazardous drugs. Br J Nurs. 2022; 31:(17)S6-S10

NIOSH list of antineoplastic and other hazardous drugs in healthcare settings, 2016. 2016. (accessed 11 May 2023)

Crauste-Manciet S, Sessink PJM, Ferrari S, Jomier J-Y, Brossard D. Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators. Ann Occup Hyg. 2005; 49:(7)619-628

European Biosafety Network. Biosafety landscape in european oncology service: Europe. 2018. (accessed 11 May 2023)

Health and Safety Executive. Safe handling of cytotoxic drugs in the workplace. 2023. (accessed 9 May 2023)

Assessing the risk of handling monoclonal antibodies. (accessed 9 May 2023)

Lawson CC, Rocheleau CM, Whelan EA Occupational exposures among nurses and risk of spontaneous abortion. Am J Obstet Gynecol. 2012; 206:327.e1-8

McDiarmid Oliver MS, Roth TS, Rogers B, Escalante C. Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs. J Occup Environ Med. 2010; 52:1028-1034

NIOSH list of antineoplastic and other hazardous drugs in healthcare settings, 2016. 2016.

Petralia SA, Dosemeci M, Estes Adams E, Hoar Zahm S. Cancer mortality among women employed in health care occupations in 24 U.S. States, 1984–1993. Am J Indust Med. 1999; 36:(1)159-165

Roussel C, Witt KL, Shaw PB, Connor TH. Meta-analysis of chromosomal aberrations as a biomarker of exposure in healthcare workers occupationally exposed to antineoplastic drugs. Mutat Res. 2019; 781:207-217

Ryan M, Lam N, Wright K Clinical Oncology Society of Australia Position Statement: 2022 update to the safe handling of monoclonal antibodies in healthcare settings. Asia-Pac J Clin Oncol. 2023;

Guidance on handling of injectable cytotoxic drugs in clinical areas in NHS Hospitals in the UK. 2018. (accessed 9 May 2023)

Skov T, Lynge E, Maarup B, Olsen J, Rørth M, Winthereik H. Risks for physicians handling antineoplastic drugs. Lancet. 1990; 336:(8728)

Skov T, Maarup B, Olsen J, Rørth M, Winthereik H, Lynge E. Leukaemia and reproductive outcome among nurses handling antineoplastic drugs. Br J Ind Med. 1992; 49:855-861

Vyas N, Turner A, Clark JM, Sewell GJ. Evaluation of a closed-system cytotoxic transfer device in a pharmaceutical isolator. J Oncol Pharm Pract. 2016; 22:(1)10-9

Wick C, Slawson MH, Jorgenson JA, Tyler LS. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health Syst Pharm. 2003; 60:(22)2314-2320

Taking steps to protect cancer nurses from exposure to hazardous drugs

25 May 2023
Volume 32 · Issue 10


Freelance medical writer Christine Clark ( reports on an online meeting held in March 2023 as part of a series on the risks of exposure to hazardous drugs for nurses working in oncology

The fourth webinar discussing the results of research into the risks to nurses of occupational exposure to hazardous drugs and the protective role of closed system transfer devices (CSTDs) was held on 30 March 2023. The webinar was organised by Aesculap Academia, the educational arm of B Braun Medical Ltd. The earlier webinars in this series, held in November 2020 and April 2021, were reported in previous BJN oncology supplements (Clark, 2021a; 2021b; 2022).

Opening the meeting the chair, Naomi Clatworthy (Acute Oncology Nurse Consultant, Royal Devon University Healthcare NHS Foundation Trust) commented that previous meetings in this series generated excellent feedback. Some 500 people took part in this webinar and an audience poll at the start showed that 54% of respondents were ‘very concerned’ about the health effects of hazardous drugs.

‘Biologically important exposure [to hazardous drugs] is occurring in the oncology work setting’, Dr Melissa McDiarmid (Professor of Medicine and Epidemiology, University of Maryland School of Medicine) told the audience.

Register now to continue reading

Thank you for visiting British Journal of Nursing and reading some of our peer-reviewed resources for nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • Unlimited access to the latest news, blogs and video content